Cargando…
A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469803/ https://www.ncbi.nlm.nih.gov/pubmed/30951520 http://dx.doi.org/10.1371/journal.pbio.3000204 |
_version_ | 1783411683903930368 |
---|---|
author | Hernandez-Sanchez, Wilnelly Huang, Wei Plucinsky, Brian Garcia-Vazquez, Nelson Robinson, Nathaniel J. Schiemann, William P. Berdis, Anthony J. Skordalakes, Emmanuel Taylor, Derek J. |
author_facet | Hernandez-Sanchez, Wilnelly Huang, Wei Plucinsky, Brian Garcia-Vazquez, Nelson Robinson, Nathaniel J. Schiemann, William P. Berdis, Anthony J. Skordalakes, Emmanuel Taylor, Derek J. |
author_sort | Hernandez-Sanchez, Wilnelly |
collection | PubMed |
description | Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor of telomerase activity. The crystal structure of 5-MeCITP bound to the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, in which the nucleobase is flipped in the active site. In this orientation, the methoxy group of 5-MeCITP extends out of the canonical active site to interact with a telomerase-specific hydrophobic pocket formed by motifs 1 and 2 in the fingers domain and T-motif in the RNA-binding domain of the telomerase reverse transcriptase. In vitro data show that 5-MeCITP inhibits telomerase with a similar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT). In addition, cell-based studies show that treatment with the cell-permeable nucleoside counterpart of 5-MeCITP leads to telomere shortening in telomerase-positive cancer cells, while resulting in significantly lower cytotoxic effects in telomerase-negative cell lines when compared with AZT treatment. |
format | Online Article Text |
id | pubmed-6469803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-64698032019-05-03 A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity Hernandez-Sanchez, Wilnelly Huang, Wei Plucinsky, Brian Garcia-Vazquez, Nelson Robinson, Nathaniel J. Schiemann, William P. Berdis, Anthony J. Skordalakes, Emmanuel Taylor, Derek J. PLoS Biol Research Article Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor of telomerase activity. The crystal structure of 5-MeCITP bound to the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, in which the nucleobase is flipped in the active site. In this orientation, the methoxy group of 5-MeCITP extends out of the canonical active site to interact with a telomerase-specific hydrophobic pocket formed by motifs 1 and 2 in the fingers domain and T-motif in the RNA-binding domain of the telomerase reverse transcriptase. In vitro data show that 5-MeCITP inhibits telomerase with a similar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT). In addition, cell-based studies show that treatment with the cell-permeable nucleoside counterpart of 5-MeCITP leads to telomere shortening in telomerase-positive cancer cells, while resulting in significantly lower cytotoxic effects in telomerase-negative cell lines when compared with AZT treatment. Public Library of Science 2019-04-05 /pmc/articles/PMC6469803/ /pubmed/30951520 http://dx.doi.org/10.1371/journal.pbio.3000204 Text en © 2019 Hernandez-Sanchez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hernandez-Sanchez, Wilnelly Huang, Wei Plucinsky, Brian Garcia-Vazquez, Nelson Robinson, Nathaniel J. Schiemann, William P. Berdis, Anthony J. Skordalakes, Emmanuel Taylor, Derek J. A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title | A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title_full | A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title_fullStr | A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title_full_unstemmed | A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title_short | A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
title_sort | non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469803/ https://www.ncbi.nlm.nih.gov/pubmed/30951520 http://dx.doi.org/10.1371/journal.pbio.3000204 |
work_keys_str_mv | AT hernandezsanchezwilnelly anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT huangwei anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT plucinskybrian anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT garciavazqueznelson anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT robinsonnathanielj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT schiemannwilliamp anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT berdisanthonyj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT skordalakesemmanuel anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT taylorderekj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT hernandezsanchezwilnelly nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT huangwei nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT plucinskybrian nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT garciavazqueznelson nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT robinsonnathanielj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT schiemannwilliamp nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT berdisanthonyj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT skordalakesemmanuel nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity AT taylorderekj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity |